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Correspondence334patients with rhabdomyolysis secondary to
trauma.6
† Whilst we agree that factors such as heterophile
antibodies (HA) can cause interference in immu-
noassays (such as that used to assay cTnI) and thus
produce true false positives, the incidence of
interfering HAs is low.7 Furthermore, the majority
of studies assessing the prognostic significance of
cTnI make no effort to screen and correct for HAs.
Our study demonstrated that up to one third of
patients undergoing bypass surgery for critical lower
limb ischaemia (CLI) sustained peri-operative myo-
cardial injury as manifest by an elevated cTnI.
Regardless of the mechanism of injury, it is clear
that myocardial cell damage occurs in a significant
proportion of these patients and there is abundant
evidence to demonstrate that acute elevations in cTnI
are associated with adverse short and long-term
prognosis in patients undergoing major vascular
surgery.8,9 Jeganathan and Walker are keen to stress
the importance of clinical context when investigating
patients with CLI for coronary artery disease. This
group has such a high incidence of coronary artery
disease that further treatment of those patients
experiencing a cTnI rise seems entirely appropriate.
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Vainas et al. investigated a possible effect of a 3-day
azithromycin course on peripheral arterial disease
(PAD) during 2 years. Peripheral arterial compli-
cations were observed in 23% of azithromycin-treated
and 20% of placebo-treated patients. Vainas et al.
concluded that a short-term course of azithromycin
does not influence PAD.1 In contrast, our group
showed that administration of roxithromycin for
28 days prevents progression of PAD in Chlamydia
pneumoniae seropositive men. Limitation of walking
distance to 200 m or less was observed in 20% of
roxithromycin-treated and 65% of placebo-treated
patients. Five invasive revascularizations were
carried out in 20% of roxithromycin-treated patients
compared to 29 interventions in 45% of placebo-
treated patients during 2.7 years.2
The striking difference between the two studies
regarding the effect of macrolides on PAD needs
explanation. Patients were selected differently for the
two studies. Vainas et al. selected patients who either
had an IgA titerO16 (mean 28) EIUs or were C.
pneumoniae seronegative. In contrast, an IgG
titerR1/128 was inclusion criterion of our study,
median C. pneumoniae antibody titers were 1/256
(IgG) and 1/64 (IgA). The percentage of patients
undergoing severe impairment of PAD clearly
differed between the placebo group of Vainas’ study
(20%) and our study (65%). Duration of antibiotic
treatment was different in the two studies. Azithro-
mycin administered for 3 days—though character-
ized by a serum and tissue half life time of several
days—is expected to have a less accentuated
Correspondence 335anti-chlamydial effect than roxithromycin given for
28 days in our study.
A possible effect of macrolides on PAD depends on
(I) selection of patients with clinically relevant
endovascular infection with C. pneumoniae and (II)
treatment of these patients with an effective regimen.
The relevance of patient selection is often under-
estimated. We selected—in contrast to Vainas et al.—
patients with high antibody titers (IgGR1/128) and a
high clinical activity of peripheral atherosclerosis
(severe impairment of PAD was observed in 65% of
the placebo-treated patients). These features might
indicate endovascular chlamydial disease. In our
study, a significant association between C. pneumoniae
seropositivity and incidence of PAD confirmed the
involvement of C. pneumoniae.3 It is worth noting, that
C. pneumoniae seropositivity was also significantly
related to peripheral arterial events in the study by
Vainas et al.1
It will be subject of further studies to evaluate
whether a high clinical activity of peripheral athero-
sclerosis in presence of high C. pneumoniae antibody
titers is a reliable criterion for patient selection and
whether administration of macrolides during 1
month is an optimum regimen. A further indicator
of endovascular infection with C. pneumoniae might
be elevated concentrations of serum homocysteine.4
In both Vainas’ and our study, C. pneumoniae
antibodies were preferentially associated with ather-
osclerosis of peripheral arteries. Preference of C.
pneumoniae for peripheral arteries is conceivable since
peripheral arteries have a different embryological
origin and a different histological constitution than
coronary and cerebral arteries.5
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We appreciate the interest of Krayenbuehl and
colleagues in our recently published paper1 although
we believe that their conclusions need some re-
consideration.
Despite the promising initial reports suggesting a
favourable effect of antibiotics on coronary events,
recently published randomised clinical trails, enrol-
ling more than 10,000 patients with acute and/or
chronic coronary artery disease, failed to demonstrate
any beneficial effect of prolonged antibiotic treatment
(3 months–1 year) on coronary artery disease
progression.2–4
The assumption that Chlamydia pneumoniae is
preferentially associated with peripheral arterial
disease (PAD) and that antibiotic treatment of
selected PAD-patients may prove effective needs
some careful evaluation. Despite the different devel-
opmental origin of peripheral arteries, early histo-
logical studies have shown that C. pneumoniae DNA
and proteins were ubiquitously present in athero-
sclerotic plaques throughout the body.5 Furthermore,
it is believed that, after a respiratory tract infection, C.
pneumoniae reaches the vasculature through infected
alveolar macrophages.6 To the best of our knowledge,
no regional differences in leucocyte–endothelial
interactions have been reported, so that preferential
homing of infected monocytes to peripheral athero-
sclerotic sites on the basis of different vascularEur J Vasc Endovasc Surg Vol 30, September 2005
